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Intravenous and oral etoposide (VP 16-213) were tested in two sequential phase II trials in che- 
motherapy-naive patients with malignant pleural mesothelioma. In the first trial, etoposide was 
given intravenously (i.v.) at a dose of 150 mglm’ on days 1, 3 and 5 every 3 weeks. The second trial 
investigated a daily oral dose of 100 mg for 21 days followed by a 2-week treatment-free period, and 
then recycling. In both trials, the treatment was given until disease progression, intolerable toxicity 
or patient refusal. In the i.v. trial, 49 patients were included, 2 patients were ineligible. The oral 
trial recruited 45 patients, 4 patients were not eligible. In both trials, the main side-effects were 
moderate leucopenia, alopecia, nausea and vomiting. Two partial responses (4%) and three partial 
responses (7’) were reported in the i.v. and oral trials, respectively. The median survival was 29 
weeks and 38 weeks in the i.v. and oral trials, respectively. In conclusion, further investigation of 
etoposide in malignant mesothelioma is not recommended. :j, 1997 Elsevier Science Ltd. 
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INTRODUCTION 
MALIGNANT MEsoTHELIoMA may originate from the pleura, 
peritoneum, pericardium or tunica vaginalis. Apart from the 
rare and early localised forms, this tumour is unresectable 
and most patients die within 1 year after diagnosis. Since 
the first description of mesothelioma in the early 193Os, the 
incidence based on tumour registries has steadily increased 
and is expected to continue to rise in the next decade [ 11. 
Published estimates for incidence in Europe are rare. In the 
Nantes-Saint Nazaire region, France, the incidence during 
the period 19851992 was 10.9 per million inhabitants ver- 
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sus 8.7 for the period 19751984 and 2.6 for the period 
1956-1974 [2]. In Norway, the age-adjusted incidence rate 
for men increased from 4 per million in the period 1960- 
1969 to 14 per million in the period 1980-1988 [3]. In the 
United States the annual incidence of mesothelioma is 
roughly estimated to be 2200 new cases [4-61. 
Despite treatment, mesothelioma remains a rapidly pro- 
gressing and lethal malignancy. Various chemotherapeutic 
agents have been tested in mesothelioma. A recent review of 
phase II trials noted that no drugs have consistently induced 
a response rate greater than 20% [7]. 
Etoposide (VP1 6-2 13), a semisynthetic podophyllotoxin 
derivative, is an inhibitor of DNA topoisomerase II resulting 
in stabilisation of DNA strand breaks [8]. Etoposide has 
demonstrated considerable efficacy against a broad spec- 
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trum of tumours [9]. The drug is thought to act in the late 
S and early G2 phases of the cell cycle, and is highly sche- 
dule dependent [lo]. Repeated administration of etoposide 
has been reported to be superior to a 24 h infusion in small 
cell lung cancer (SCLC) [l 11. The same investigators also 
reported that an 8-day intravenous (i.v.) regimen versus the 
5-day regimen showed no improvement in efficacy [ 121. 
Daily oral etoposide showed a 23% response rate and was 
well tolerated in refractory SCLC [ 131. Activity of oral eto- 
poside has also been reported in patients with germ cell 
tumours who previously failed on cisplatin, etoposide or 
both drugs [14] and heavily pretreated patients with lym- 
phoma [ 151. Interestingly, partial responses have been 
reported in 5 lymphoma patients out of the 9 previously 
treated with iv. etoposide [15]. 
In mesothelioma, scanty data are available in the litera- 
ture on the activity of etoposide on a small number of 
patients [16-181. The EORTC LCCG initiated two con- 
secutive phase II trials aimed at evaluating the efficacy and 
safety of i.v. and oral etoposide in malignant mesothelioma. 
PATIENTS AND METHODS 
Patient inclusion criteria for both trials were: histologi- 
cally confirmed malignant pleural mesothelioma, no prior 
chemotherapy, no radiotherapy including all target lesions, 
radiologically bidimensionally or unidimensionally measur- 
able lesions, the sole presence of pleural effusion was not 
acceptable as a parameter of response, no intracavitary cyto- 
toxic drugs, ECOG performance status 22, age 575 years, 
white blood cell (WBC) count 23.5 x 109/1, platelets 
2100 x 109/1, bilirubin 125umoli1, and informed consent. 
Patients should not have had any signs of chronic disease, 
active infection, other malignancies or symptoms of central 
nervous system (CNS) metastases. For responding cases, a 
pathology review by the EORTC mesothelioma pathology 
panel was mandatory. Only cases classified as definite, prob- 
able or possible mesothelioma [ 191 were considered eligible 
for these two trails. 
Tumour extension was classified according to a system 
modified by Butchart and associates [20, 211 as follows: 
stage I, tumour confirmed to homolateral visceral pleura, 
lung or pericardium; stage IIA, tumour invading chest wall 
or involving mediastinum (oesophagus, heart) or presence 
of lymph nodes within the chest; stage IIB, involvement of 
contralateral pleura; stage III, tumour penetrating dia- 
phragm to involve peritoneum directly or the presence of 
lymph nodes outside the chest; stage IV, distant blood- 
borne metastases. 
In the first trial, etoposide was given iv. at a dose of 
150 mg/m2 on days 1, 3 and 5 every 3 weeks. The drug, 
supplied as a 100 mg solution in ampoules, was dissolved in 
normal saline at a maximum concentration of 0.6 mgiml. 
The infusion time was at least 30 min. The second trial 
investigated etoposide given orally at a daily dose of 100 mg 
capsules (Vepesid) for 21 days followed by a 2-week treat- 
ment-free period, and then recycle. In both trials, the treat- 
ment was given until disease progression, intolerable toxicity 
or patient refusal. 
The drug administration was postponed by 1 week in 
case of incomplete haematological recovery (WBC count 
23.0 x IO90 and platelets 2100 x 109/1) from the prior 
course. If the treatment was delayed because of myelosup- 
pression at scheduled retreatment, or if the WBC nadir 
during the previous cycle was Cl.0 x 109/1, drug dosage was 
reduced to 75%. If the treatment was delayed for 3 or more 
weeks, the treatment was discontinued. Dose escalation was 
not allowed. 
The tumour was assessed by chest X-ray and computer 
tomography (CT) scan before starting the treatment and 
every three cycles thereafter. The response was classified 
according to the World Health Organization Criteria [22]. 
Duration of response and survival were estimated from the 
start of chemotherapy and the estimates at different time 
points were based on the Kaplan-Meier technique [23]. 
The sample size calculation was based on the two-stage 
Gehan’s design [24] aiming at including 14 patients and 
then adding additional patients for each response seen in 
the first stage. This guarantees that the probability of an 
active treatment (real response rate 220%) exhibiting no re- 
sponse in the first 14 patients (that is, false-negative result) 
is 0.05 and allows estimation of the therapeutic effectiveness 
with a standard error of 10%. 
RESULTS 
Between April 1988 and October 1989, 49 patients were 
registered into the iv. etoposide trial. Two patients were 
ineligible because histological diagnosis was considered 
“probably not a mesothelioma” in 1 patient and the ECOG 
performance status for the other patient was 3. The oral 
etoposide trial recruited 45 patients between April 1990 and 
February 1992. 4 patients were not eligible because of 
incorrect diagnosis (metastatic pancreatic carcinoma and 
thymoma) in 2, prior chemotherapy in 1 and the absence of 
measurable disease in another. 
Patient and tumour characteristics are present in Table 1. 
The male/female ratio was 10: 1. The i.v. trial recruited 
more patients with sarcomatous histological subtype than 
the oral etoposide trial. The majority of patients presented 
with a relatively early stage of the disease. 
The median number of administered cycles was three in 
both trials and varied between 1 and 12 in the i.v. trial and 
between 1 and 7 in the oral trial. The median total dose of 
etoposide was 1350 mg/m2 (maximum 5400 mg/m’) and 
6624 mg (maximum 14 700 mg) in the i.v. and oral trials, 
respectively. 
In the iv. trial, the dose was reduced because of myelo- 
suppression in 3 cases, because of weight loss in 1 patient 
and because of dyspnoea in another patient. Delays were 
reported in 8 patients: 3 due to haematological toxicity, and 
5 for reasons unrelated to toxicity. In the oral etoposide 
trial, dose reduction was documented in 3 patients: one 
because of poor general conditions and treatment-unrelated 
in 2 other patients. Treatment delays were reported for 5 
patients in the oral etoposide trial: 2 due to haematological 
toxicity and 3 were considered unrelated to treatment. 
In the i.v. trial, two early deaths were reported. One 
patient died 2 weeks after starting the treatment due to 
rapidly progressing disease, with no substantial toxicity. 
Another patient died at home 2 weeks after the start of the 
first cycle. During this cycle, no severe toxicity was 
reported. No autopsy was performed and a precise cause of 
death could not be established. 
The most common side-effects were leucopenia, nausea, 
vomiting and alopecia (Table 2). In the i.v. trial, the me- 
dian nadir values for leucocytes and platelets were 
3.5 x IO911 (range 0.5-9.0) and 255 x lo911 (range 119- 
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Table 1. Patient and turnour characteristics at enty 
Characteristic 
Etoposide i.v. 
n 
(n = 47) 
(%) 
Oral etoposide 
M 
(n = 41) 
(o/o) 
Age (years) 
median 
(range) 
Sex 
male 
female 
ECOG performance status 
0 
1 
2 
Histological subtype 
epithelial 
sarcomatous 
mixed 
undefined 
Clinical stage 
IIA 
IIB 
III 
IV 
unknown 
Disease measurability 
bidimensionally 
unidimensionally 
(4;:72) 
45 
2 
11 (23) 
26 (55) 
10 (21) 
18 
21 
3 
5 
15 (32) 12 
23 (49) 18 
1 (2) 2 
3 (6) 7 
3 (6) 2 
2 4 0 
19 (40) 27 
28 (60) 14 
(96) 35 (85) 
(4) 6 (15) 
(38) 18 
(45) 6 
(6) 5 
(11) 12 
57 
(30-73) 
13 
21 
7 
(32) 
(51) 
(17) 
(44) 
(15) 
(12) 
(29) 
(29) 
(44) 
(5) 
(17) 
(5) 
(66) 
(34) 
639), with 6% and 0% grade 3-4 toxicity, respectively. In 
the oral trial, the median nadir values for leucocytes and 
platelets were 4.0 x lo911 (range 0.9-12.6) and 274 x 109/1 
(range 24-778), with 12% and 2% grade 3-4 toxicity, re- 
spectively. Hair loss was complete in 17% and 24% in the 
i.v. and oral trials, respectively. Nausea and vomiting were 
observed in 55% (grade 3-4 in 4%) and 66% (grade 3-4 in 
10%) of the patients in the i.v. and oral trials, respectively. 
Drug fever was reported in a total of 7 patients; 2 in the i.v. 
trial and 5 in the oral trial. Mucositis, local phlebitis, diar- 
rhoea and allergy were observed infrequently and were not 
severe. 
In the i.v. trial, partial responses were documented in 2 
patients (4%, 95% exact confidence interval: l-15%). 
Stable disease was observed in 15 patients and 25 patients 
progressed on treatment. 2 patients died after only one 
cycle (see above). The response was not assessable in 3 
other patients because they had received only one cycle: due 
to poor performance status in 1 patient, hypotension and 
pulmonary oedema (possibly due to cardiac toxicity) in 
another patient, and the third patient suffered from severe 
anaphylactic reaction (dyspnoea and bronchial spasm 2 min 
after the first infusion). One response lasted for 32 weeks 
and the other patient was lost to follow-up after 28 weeks 
with no progression. The median survival for all eligible 
patients was 29 weeks (Figure 1). 
In the oral etoposide trial, 3 patients achieved partial re- 
sponse (7%, 95% exact confidence interval: 2-20%), 14 
patients had stable disease, 22 progressed on treatment, 1 
patient died after one cycle due to malignant disease and 
the response could not be evaluated in another patient, who 
received only one cycle due to severe thrombocytopenia 
leading to a haemorrhage. The three partial responses lasted 
Table 2. Side-effects: worst grade reported during the treatment period 
Side-effect 
Etoposide i.v. (n = 47) Oral etoposide (n = 41) 
Any toxicity grade 3-4 Any toxicity grade 3-4 
n (%) II (%) n (%) n W) 
Leucopenia 27 (57) 
Thrombocytopenia 0 (0) 
Nausea/vomiting 26 (55) 
Diarrhoea 4 (9) 
Liver toxicity 0 (0) 
Drug fever 2 (4) 
Allergy 3 (6) 
Cutaneous reaction 0 (0) 
Alopecia 22 (47) 
Infection 2 (4) 
Mucositis 2 (4) 
3 (6) 
0 (0) 
2 (4) 
0 (0) 
0 (0) 
0 (0) 
1 (2) 
0 (0) 
8 (17) 
0 (0) 
1 (2) 
20 
3 
27 
5 
5 
5 
29 
3 
2 
(49) 
(7) 
(66) 
(12) 
(12) 
(12) 
(2) 
(2) 
(71) 
(7) 
(5) 
5 
1 
4 
1 
0 
0 
0 
1 
10 
0 
0 
(12) 
(2) 
(10) 
(2) 
(0) 
(0) 
(0) 
(2) 
(24) 
(0) 
(0) 
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80 
60 
n 0 
41 42 Intravenous etoposide 
41 34 Oral etoposide - - - - 
I 
0 6 12 18 24 30 36 
Months 
Number of patients at risk: 
47 23 9 3 2 1 i.v. etoposide 
41 26 12 5 3 1 Oral etoposide 
Figure 1. Duration of survival (n, number of patients; 0, observed number of events). 
for 26, 30 and 52 weeks. The median survival for eligible 
patients was 37 weeks (Figure 1). 
DISCUSSION 
Both trials demonstrate a low activity of etoposide in 
mesothelioma when given iv. for three alternative days or 
with chronic oral route. We could not prove any advantage 
of giving oral etoposide for a prolonged period. Oral etopo- 
side is known to yield a considerable intrapatient and inter- 
patient variation in drug bioavailability [25]. Assuming a 
40-50% oral bioavailability, the average actually delivered 
total dose in the oral etoposide trial was roughly equivalent 
to that in the i.v. trial (6624 mg and 1350 mgim’, respect- 
ively) . 
Toxicity in general was similar for the two different 
routes of administration. However, the relatively modest 
leucopenia, especially in the oral route trial, could be par- 
tially explained by the protocol requirement for haematolo- 
gical evaluation. In the i.v. trial, blood cell counts were 
required weekly during the first two cycles and were there- 
after mandatory only prior to starting the next cycle. In the 
oral trial, a complete blood count was required only at days 
22, 29 and 36 of each cycle. 
The accrual of both trials was higher than initially 
planned, because some partial responses were not sub- 
sequently confirmed by the study coordinator. These 
unconfirmed responses led to the continuation of recruit- 
ment to over 40 patients in both trials, in accordance with 
the study design. 
We observed a difference in survival in favour of the oral 
route. However, one should not overinterpret the apparent 
difference in the duration of survival because of the lack of 
randomisation, and because of the poor activity of the treat- 
ment. This difference could be simply due to an imbalance 
in some prognostic factors such as sex (4% females in the 
i.v. trial versus 15% in the oral trial) or having a purely sar- 
comatous histological subtype (50% in the i.v. trial versus 
21% in the oral trial). 
Because etoposide combined with cisplatin has been 
shown to be synergistic in animal models [26] and has pro- 
ven efficacious in other tumours, two studies investigated 
this combination in malignant pleural mesothelioma. This 
combination gave only three partial responses in 27 eligible 
patients (11%) in a Canadian study [27]. In another small 
study of 25 patients, oral etoposide for 15 days was associ- 
ated with high-dose weekly cisplatin [28]; a response rate of 
24% (one complete response and five partial responses) was 
observed. This somewhat encouraging result may well be 
explained by the intensive cisplatin dosing but because of 
the small number of patients enrolled, the confidence inter- 
vals of this study are rather large. 
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In conclusion, we do not think that further investigation 
of etoposide alone in mesothelioma is to be recommended 
in the dose and schedule administered in our two studies. 
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